{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T22:24:58Z","timestamp":1773181498773,"version":"3.50.1"},"reference-count":174,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,7,18]],"date-time":"2024-07-18T00:00:00Z","timestamp":1721260800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006111","name":"Minist\u00e9rio da Ci\u00eancia, Tecnologia e Ensino Superior","doi-asserted-by":"publisher","award":["LA\/P\/0008\/2020 DOI 10.54499\/LA\/P\/0008\/2020"],"award-info":[{"award-number":["LA\/P\/0008\/2020 DOI 10.54499\/LA\/P\/0008\/2020"]}],"id":[{"id":"10.13039\/501100006111","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006111","name":"Minist\u00e9rio da Ci\u00eancia, Tecnologia e Ensino Superior","doi-asserted-by":"publisher","award":["UIDP\/50006\/2020 DOI 10.54499\/UIDP\/50006\/2020"],"award-info":[{"award-number":["UIDP\/50006\/2020 DOI 10.54499\/UIDP\/50006\/2020"]}],"id":[{"id":"10.13039\/501100006111","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006111","name":"Minist\u00e9rio da Ci\u00eancia, Tecnologia e Ensino Superior","doi-asserted-by":"publisher","award":["UIDB\/50006\/2020 DOI 10.54499\/UIDB\/50006\/2021"],"award-info":[{"award-number":["UIDB\/50006\/2020 DOI 10.54499\/UIDB\/50006\/2021"]}],"id":[{"id":"10.13039\/501100006111","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmn.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Discovery Today"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1016\/j.drudis.2024.104059","type":"journal-article","created":{"date-parts":[[2024,6,12]],"date-time":"2024-06-12T22:20:56Z","timestamp":1718230856000},"page":"104059","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Targeting hematological malignancies with isoxazole derivatives"],"prefix":"10.1016","volume":"29","author":[{"given":"Monika","family":"Majirsk\u00e1","sequence":"first","affiliation":[]},{"given":"Martina Bago","family":"Pil\u00e1tov\u00e1","sequence":"additional","affiliation":[]},{"given":"Zuzana","family":"Kudli\u010dkov\u00e1","sequence":"additional","affiliation":[]},{"given":"Martin","family":"Vojtek","sequence":"additional","affiliation":[]},{"given":"Carmen","family":"Diniz","sequence":"additional","affiliation":[]}],"member":"78","reference":[{"key":"10.1016\/j.drudis.2024.104059_b0005","unstructured":"Cancer. Accessed February 13, 2024. https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/cancer."},{"key":"10.1016\/j.drudis.2024.104059_b0010","doi-asserted-by":"crossref","first-page":"3425","DOI":"10.1002\/cam4.1461","article-title":"Incidence and survival of hematological cancers among adults ages \u226575 years","volume":"7","author":"Krok-Schoen","year":"2018","journal-title":"Cancer Med"},{"key":"10.1016\/j.drudis.2024.104059_b0015","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22126321","article-title":"From the (epi)genome to metabolism and vice versa; examples from hematologic malignancy","volume":"22","author":"Karagianni","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.drudis.2024.104059_b0020","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1182\/blood-2017-02-734541","article-title":"Diagnosis and classification of hematologic malignancies on the basis of genetics","volume":"130","author":"Taylor","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.drudis.2024.104059_b0025","doi-asserted-by":"crossref","DOI":"10.1038\/s41408-023-00853-3","article-title":"Global burden of hematologic malignancies and evolution patterns over the past 30 years","volume":"13","author":"Zhang","year":"2023","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.drudis.2024.104059_b0030","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41408-022-00728-z","article-title":"Survival trends in hematological malignancies in the Nordic countries through 50 years","volume":"12","author":"Hemminki","year":"2022","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.drudis.2024.104059_b0035","unstructured":"Klausner R. Leukemia, Lymphoma, and multiple myeloma: toward a new understanding \u2013 June 21, 2001. Published online 2001."},{"key":"10.1016\/j.drudis.2024.104059_b0040","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1111\/imr.12245","article-title":"Novel immunotherapies for hematologic malignancies","volume":"263","author":"Nelson","year":"2015","journal-title":"Immunol Rev"},{"key":"10.1016\/j.drudis.2024.104059_b0045","article-title":"FDA-approved drugs for hematological malignancies\u2014the last decade review","volume":"14","author":"Sochacka-\u0107wik\u0142a","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.drudis.2024.104059_b0050","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1055\/a-0898-7347","article-title":"Highlights on specific biological targets; cyclin-dependent kinases, epidermal growth factor receptors, ras protein, and cancer stem cells in anticancer drug development","volume":"69","author":"Hawash","year":"2019","journal-title":"Drug Res"},{"key":"10.1016\/j.drudis.2024.104059_b0055","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1517\/17460441.2015.997205","article-title":"Development and application of PI3K assays for novel drug discovery","volume":"10","author":"Yanamandra","year":"2015","journal-title":"Expert Opin Drug Discov"},{"key":"10.1016\/j.drudis.2024.104059_b0060","doi-asserted-by":"crossref","first-page":"14460","DOI":"10.1002\/jcp.28215","article-title":"Upstream regulators of phosphoinositide 3-kinase and their role in diseases","volume":"234","author":"Wang","year":"2019","journal-title":"J Cell Physiol"},{"key":"10.1016\/j.drudis.2024.104059_b0065","doi-asserted-by":"crossref","first-page":"336","DOI":"10.2174\/1871520610909030336","article-title":"Antimitotic chalcones and related compounds as inhibitors of tubulin assembly","volume":"9","author":"Ducki","year":"2009","journal-title":"Anticancer Agents Med Chem"},{"key":"10.1016\/j.drudis.2024.104059_b0070","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1385\/CBB:38:1:1","article-title":"Evaluation of antimitotic agents by quantitative comparisons of their effects on the polymerization of purified tubulin","volume":"38","author":"Hamel","year":"2003","journal-title":"Cell Biochem Biophys"},{"key":"10.1016\/j.drudis.2024.104059_b0075","doi-asserted-by":"crossref","first-page":"2670","DOI":"10.1021\/jm020077t","article-title":"One-pot synthesis of benzo[b]furan and indole inhibitors of tubulin polymerization","volume":"45","author":"Flynn","year":"2002","journal-title":"J Med Chem"},{"key":"10.1016\/j.drudis.2024.104059_b0080","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.3390\/biom12121843","article-title":"Recent Advances of tubulin inhibitors targeting the colchicine binding site for cancer therapy","volume":"12","author":"Hawash","year":"2022","journal-title":"Biomolecules"},{"key":"10.1016\/j.drudis.2024.104059_b0085","article-title":"Imatinib in chronic myeloid leukemia: an overview","volume":"6","author":"Sacha","year":"2014","journal-title":"Mediterr J Hematol Infect Dis"},{"key":"10.1016\/j.drudis.2024.104059_b0090","doi-asserted-by":"crossref","first-page":"731","DOI":"10.3390\/cancers12030731","article-title":"Tyrosine kinase inhibitors in cancer: breakthrough and challenges of targeted therapy","volume":"12","author":"Pottier","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.drudis.2024.104059_b0095","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1038\/s12276-022-00864-3","article-title":"Molecular targeted therapy for anticancer treatment","volume":"54","author":"Min","year":"2022","journal-title":"Exp Mol Med"},{"key":"10.1016\/j.drudis.2024.104059_b0100","doi-asserted-by":"crossref","first-page":"703","DOI":"10.3390\/cancers15030703","article-title":"Current state and future challenges for PI3K inhibitors in cancer therapy","volume":"15","author":"Sirico","year":"2023","journal-title":"Cancers"},{"key":"10.1016\/j.drudis.2024.104059_b0105","doi-asserted-by":"crossref","first-page":"2201","DOI":"10.3390\/molecules27072201","article-title":"Revisiting proteasome inhibitors: molecular underpinnings of their development, mechanisms of resistance and strategies to overcome anti-cancer drug resistance","volume":"27","author":"Leonardo-sousa","year":"2022","journal-title":"Molecules"},{"key":"10.1016\/j.drudis.2024.104059_b0110","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1182\/asheducation-2013.1.151","article-title":"Immunotherapeutic strategies including transplantation: eradication of disease","volume":"2013","author":"Gribben","year":"2013","journal-title":"Hematology"},{"key":"10.1016\/j.drudis.2024.104059_b0115","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.coi.2014.01.004","article-title":"New insights into cancer immunoediting and its three component phases \u2014 elimination, equilibrium and escape","volume":"27","author":"Mittal","year":"2014","journal-title":"Curr Opin Immunol"},{"key":"10.1016\/j.drudis.2024.104059_b0120","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41392-023-01521-5","article-title":"Immunotherapy in hematologic malignancies: achievements, challenges and future prospects","volume":"8","author":"Tang","year":"2023","journal-title":"Signal Transduct Targeted Therapy"},{"key":"10.1016\/j.drudis.2024.104059_b0125","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1038\/nature10673","article-title":"Cancer immunotherapy comes of age","volume":"480","author":"Mellman","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.drudis.2024.104059_b0130","doi-asserted-by":"crossref","first-page":"9903","DOI":"10.1007\/s11033-022-07525-8","article-title":"Immunotherapy: an alternative promising therapeutic approach against cancers","volume":"49","author":"Gupta","year":"2022","journal-title":"Mol Biol Rep"},{"key":"10.1016\/j.drudis.2024.104059_b0135","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/ni.3682","article-title":"\u201cFinal common pathway\u201d of human cancer immunotherapy: targeting random somatic mutations","volume":"18","author":"Tran","year":"2017","journal-title":"Nat Immunol"},{"key":"10.1016\/j.drudis.2024.104059_b0140","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2014\/701493","article-title":"Target therapy in hematological malignances: new monoclonal antibodies","volume":"2014","author":"Podhorecka","year":"2014","journal-title":"Int Sch Res Notices"},{"key":"10.1016\/j.drudis.2024.104059_b0145","doi-asserted-by":"crossref","first-page":"1017990","DOI":"10.3389\/fimmu.2022.1017990","article-title":"Reshaping the tumor microenvironment: the versatility of immunomodulatory drugs in B-cell neoplasms","volume":"13","author":"Guo","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.drudis.2024.104059_b0150","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1615\/CritRevImmunol.2020036178","article-title":"Current challenges and strategies for chimeric antigen receptor-T-cell therapy for solid tumors","volume":"41","author":"Chen","year":"2021","journal-title":"Crit Rev\u2122 Immunol"},{"key":"10.1016\/j.drudis.2024.104059_b0155","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1001\/jamaoncol.2021.0168","article-title":"Radiotherapy to enhance chimeric antigen receptor T-cell therapeutic efficacy in solid tumors: a narrative review","volume":"7","author":"Hauth","year":"2021","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.drudis.2024.104059_b0160","doi-asserted-by":"crossref","first-page":"6091","DOI":"10.3390\/ijms21176091","article-title":"Drug resistance in hematological malignancies","volume":"21","author":"Auberger","year":"2020","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.drudis.2024.104059_b0165","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1002\/ijc.33934","article-title":"Cancer risk and mortality after solid organ transplantation: a population-based 30-year cohort study in Finland","volume":"150","author":"Friman","year":"2022","journal-title":"Int J Cancer"},{"key":"10.1016\/j.drudis.2024.104059_b0170","doi-asserted-by":"crossref","DOI":"10.1259\/bjr.20180390","article-title":"Review of risk factors of secondary cancers among cancer survivors","volume":"92","author":"Demoor-Goldschmidt","year":"2019","journal-title":"Br J Radiol"},{"key":"10.1016\/j.drudis.2024.104059_b0175","first-page":"1","article-title":"Secondary cancer risk after radiation therapy for breast cancer with different radiotherapy techniques","volume":"10","author":"Zhang","year":"2020","journal-title":"Sci Rep"},{"key":"10.1016\/j.drudis.2024.104059_b0180","doi-asserted-by":"crossref","first-page":"85","DOI":"10.3857\/roj.2018.00290","article-title":"Radiation induced secondary malignancies: a review article","volume":"36","author":"Dracham","year":"2018","journal-title":"Radiat Oncol J"},{"key":"10.1016\/j.drudis.2024.104059_b0185","doi-asserted-by":"crossref","first-page":"3065","DOI":"10.1016\/j.bmc.2018.05.013","article-title":"The recent progress of isoxazole in medicinal chemistry","volume":"26","author":"Zhu","year":"2018","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/j.drudis.2024.104059_b0190","author":"Rahbak","year":"2001","journal-title":"Isoxazole Alkaloids"},{"key":"10.1016\/j.drudis.2024.104059_b0195","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12272-013-0262-8","article-title":"Synthesis, analgesic, anti-inflammatory and in vitro antimicrobial activities of some novel isoxazole coupled quinazolin-4(3H)-one derivatives","volume":"44","author":"Saravanan","year":"2021","journal-title":"Arch Pharm Res"},{"key":"10.1016\/j.drudis.2024.104059_b0200","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1111\/ane.12017","article-title":"Zonisamide in clinical practice","volume":"126","author":"Dupont","year":"2012","journal-title":"Acta Neurol Scand"},{"key":"10.1016\/j.drudis.2024.104059_b0205","doi-asserted-by":"crossref","DOI":"10.3390\/molecules23071545","article-title":"Synthesis, immunosuppressive properties, and mechanism of action of a new isoxazole derivative","volume":"23","author":"Maczynski","year":"2018","journal-title":"Molecules"},{"key":"10.1016\/j.drudis.2024.104059_b0210","first-page":"142","article-title":"Discovery and anti-diabetic effects of novel isoxazole based flavonoid derivatives","author":"Nie","year":"2020","journal-title":"Fitoterapia"},{"key":"10.1016\/j.drudis.2024.104059_b0215","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1021\/acs.jmedchem.6b01852","article-title":"Expeditious lead optimization of isoxazole-containing influenza A virus M2\u2013S31N inhibitors using the suzuki-miyaura cross-coupling reaction","volume":"60","author":"Li","year":"2017","journal-title":"J Med Chem"},{"key":"10.1016\/j.drudis.2024.104059_b0220","first-page":"221","article-title":"Isoxazole derivatives as anticancer agent: a review on synthetic strategies, mechanism of action and SAR studies","author":"Arya","year":"2021","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.drudis.2024.104059_b0225","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1515\/chem-2021-0078","article-title":"Synthesis, chemo-informatics, and anticancer evaluation of fluorophenyl-isoxazole derivatives","volume":"19","author":"Hawash","year":"2021","journal-title":"Open Chem"},{"key":"10.1016\/j.drudis.2024.104059_b0230","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1515\/hc-2020-0134","article-title":"Design, synthesis, and biological evaluation of phenyl-isoxazole-carboxamide derivatives as anticancer agents","volume":"27","author":"Hawash","year":"2021","journal-title":"Heterocycl Comm"},{"key":"10.1016\/j.drudis.2024.104059_b0235","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13065-022-00839-5","article-title":"Synthesis of novel isoxazole\u2013carboxamide derivatives as promising agents for melanoma and targeted nano-emulgel conjugate for improved cellular permeability","volume":"16","author":"Hawash","year":"2022","journal-title":"BMC Chem"},{"key":"10.1016\/j.drudis.2024.104059_b0240","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13065-021-00793-8","article-title":"Synthesis of novel indole-isoxazole hybrids and evaluation of their cytotoxic activities on hepatocellular carcinoma cell lines","volume":"15","author":"Hawash","year":"2021","journal-title":"BMC Chem"},{"key":"10.1016\/j.drudis.2024.104059_b0245","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.reuma.2017.07.020","article-title":"Systematic review and meta-analysis of the efficacy and safety of leflunomide and methotrexate in the treatment of rheumatoid arthritis","volume":"15","author":"Alfaro-Lara","year":"2019","journal-title":"Reumatol Clin"},{"key":"10.1016\/j.drudis.2024.104059_b0250","doi-asserted-by":"crossref","first-page":"3201","DOI":"10.2174\/1381612822666160224142648","article-title":"1,2-Benzisoxazole: a privileged structure with a potential for polypharmacology","volume":"22","author":"Uto","year":"2016","journal-title":"Curr Pharm Des"},{"key":"10.1016\/j.drudis.2024.104059_b0255","doi-asserted-by":"crossref","DOI":"10.3390\/molecules25051047","article-title":"Antimicrobial, antioxidant, and anticancer activities of some novel isoxazole ring containing chalcone and dihydropyrazole derivatives","volume":"25","author":"Shaik","year":"2020","journal-title":"Molecules"},{"key":"10.1016\/j.drudis.2024.104059_b0260","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1053\/j.seminoncol.2015.09.024","article-title":"Targeting cyclin-dependent kinases and cell cycle progression in human cancers","volume":"42","author":"Santo","year":"2015","journal-title":"Semin Oncol"},{"key":"10.1016\/j.drudis.2024.104059_b0265","doi-asserted-by":"crossref","DOI":"10.3390\/antiox12030632","article-title":"Antioxidant and anti-tumor effects of dietary vitamins A, C, and E","volume":"12","author":"Didier","year":"2023","journal-title":"Antioxidants"},{"key":"10.1016\/j.drudis.2024.104059_b0270","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/S0009-8981(99)00222-3","article-title":"Free radicals antioxidant enzymes and lipid peroxidation in different types of leukemias","volume":"293","author":"Devi","year":"2000","journal-title":"Clinica Chimica Acta"},{"key":"10.1016\/j.drudis.2024.104059_b0275","doi-asserted-by":"crossref","first-page":"3322","DOI":"10.1182\/blood-2013-04-491944","article-title":"Overproduction of NOX-derived ROS in AML promotes proliferation and is associated with defective oxidative stress signaling","volume":"122","author":"Hole","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.drudis.2024.104059_b0280","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20236003","article-title":"The role of reactive oxygen species in acute myeloid leukaemia","volume":"20","author":"Sillar","year":"2019","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.drudis.2024.104059_b0285","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/ijms22052470","article-title":"Oxidative stress and ROS-mediated signaling in leukemia: novel promising perspectives to eradicate chemoresistant cells in myeloid leukemia","volume":"22","author":"Trombetti","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.drudis.2024.104059_b0290","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fimmu.2022.889875","article-title":"Reactive oxygen species and metabolism in leukemia: a dangerous liaison","volume":"13","author":"Romo-Gonz\u00e1lez","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.drudis.2024.104059_b0295","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-022-23050-x","article-title":"In vitro and in vivo assessment of the antioxidant potential of isoxazole derivatives","volume":"12","author":"Hawash","year":"2022","journal-title":"Sci Rep"},{"key":"10.1016\/j.drudis.2024.104059_b0300","doi-asserted-by":"crossref","first-page":"747","DOI":"10.55730\/1300-0527.3364","article-title":"Synthesis of some new isoxazole compounds and their biological tyrosinase and antioxidant activities","volume":"46","author":"Fandakli","year":"2022","journal-title":"Turk J Chem"},{"key":"10.1016\/j.drudis.2024.104059_b0305","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1134\/S1070428023110143","article-title":"Efficient synthesis, antioxidant activity evaluation, and molecular docking of novel isoxazole derivatives","volume":"59","author":"Shilpa","year":"2023","journal-title":"Russian J Org Chem"},{"key":"10.1016\/j.drudis.2024.104059_b0310","doi-asserted-by":"crossref","first-page":"5034","DOI":"10.1016\/j.ejmech.2011.08.010","article-title":"Synthesis and antioxidant activity of oxazolyl\/thiazolylsulfonylmethyl pyrazoles and isoxazoles","volume":"46","author":"Padmaja","year":"2011","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.drudis.2024.104059_b0315","doi-asserted-by":"crossref","DOI":"10.1155\/2021\/6633297","article-title":"Synthesis and biological evaluation of novel isoxazole-amide analogues as anticancer and antioxidant agents","volume":"2021","author":"Eid","year":"2021","journal-title":"Biomed Res Int"},{"key":"10.1016\/j.drudis.2024.104059_b0320","doi-asserted-by":"crossref","DOI":"10.1155\/2019\/5381692","article-title":"Understanding of ROS-inducing strategy in anticancer therapy","volume":"2019","author":"Kim","year":"2019","journal-title":"Oxid Med Cell Longev"},{"key":"10.1016\/j.drudis.2024.104059_b0325","doi-asserted-by":"crossref","DOI":"10.3390\/molecules27165086","article-title":"Tyrosol derivatives, bearing 3,5-disubstituted isoxazole and 1,4-disubstituted triazole, as potential antileukemia agents by promoting apoptosis","volume":"27","author":"Abdelkafi-Koubaa","year":"2022","journal-title":"Molecules"},{"key":"10.1016\/j.drudis.2024.104059_b0330","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1038\/onc.2010.441","article-title":"ROS-mediated upregulation of Noxa overcomes chemoresistance in chronic lymphocytic leukemia","volume":"30","author":"Tonino","year":"2011","journal-title":"Oncogene"},{"key":"10.1016\/j.drudis.2024.104059_b0335","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2010\/584657","article-title":"Role for PKC in fenretinide-mediated apoptosis in lymphoid leukemia cells","volume":"2010","author":"Ruvolo","year":"2010","journal-title":"J Signal Transduct"},{"key":"10.1016\/j.drudis.2024.104059_b0340","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.taap.2015.02.005","article-title":"Quinacrine induces apoptosis in human leukemia K562 cells via p38 MAPK-elicited BCL2 down-regulation and suppression of ERK\/c-Jun-mediated BCL2L1 expression","volume":"284","author":"Changchien","year":"2015","journal-title":"Toxicol Appl Pharmacol"},{"key":"10.1016\/j.drudis.2024.104059_b0345","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1023\/A:1015331229263","article-title":"The inherent cellular level of reactive oxygen species: one of the mechanisms determining apoptotic susceptibility of leukemic cells to arsenic trioxide","volume":"7","author":"Togashi","year":"2002","journal-title":"Apoptosis"},{"key":"10.1016\/j.drudis.2024.104059_b0350","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2023.115905","article-title":"Preclinical characterization of danatinib as a novel FLT3 inhibitor with excellent efficacy against resistant acute myeloid leukemia","volume":"169","author":"Sun","year":"2023","journal-title":"Biomed Pharmacotherapy"},{"key":"10.1016\/j.drudis.2024.104059_b0355","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1080\/1042819021000002866","article-title":"FLT3 in human hematologic malignancies","volume":"43","author":"Kiyoi","year":"2002","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.drudis.2024.104059_b0360","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13065-023-00981-8","article-title":"Indole-based FLT3 inhibitors and related scaffolds as potential therapeutic agents for acute myeloid leukemia","volume":"17","author":"Ezelarab","year":"2023","journal-title":"BMC Chem"},{"key":"10.1016\/j.drudis.2024.104059_b0365","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.2217\/fon.14.105","article-title":"Quizartinib for the treatment of FLT3\/ITD acute myeloid leukemia","volume":"10","author":"Levis","year":"2014","journal-title":"Future Oncology"},{"key":"10.1016\/j.drudis.2024.104059_b0370","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/j.chembiol.2021.10.011","article-title":"Identification of a highly efficient dual type I\/II FMS-like tyrosine kinase inhibitor that disrupts the growth of leukemic cells","volume":"29","author":"Beyer","year":"2022","journal-title":"Cell Chem Biol"},{"key":"10.1016\/j.drudis.2024.104059_b0375","doi-asserted-by":"crossref","first-page":"5943","DOI":"10.2147\/OTT.S100515","article-title":"BET inhibitors in the treatment of hematologic malignancies: current insights and future prospects","volume":"9","author":"Abedin","year":"2016","journal-title":"Onco Targets Ther"},{"key":"10.1016\/j.drudis.2024.104059_b0380","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/nrg816","article-title":"The fundamental role of epigenetic events in cancer","volume":"3","author":"Jones","year":"2002","journal-title":"Nat Rev Genet"},{"key":"10.1016\/j.drudis.2024.104059_b0385","doi-asserted-by":"crossref","first-page":"7457","DOI":"10.1007\/s11033-023-08645-5","article-title":"Inhibition of CARM1 suppresses proliferation of multiple myeloma cells through activation of p53 signaling pathway","volume":"50","author":"Yang","year":"2023","journal-title":"Mol Biol Rep"},{"key":"10.1016\/j.drudis.2024.104059_b0390","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12863-021-01022-w","article-title":"Systematic pan-cancer landscape identifies CARM1 as a potential prognostic and immunological biomarker","volume":"23","author":"Qiu","year":"2022","journal-title":"BMC Genom Data"},{"key":"10.1016\/j.drudis.2024.104059_b0395","doi-asserted-by":"crossref","first-page":"52","DOI":"10.3390\/pathogens1010052","article-title":"Arginine methyltransferases are regulated by epstein-barr virus in B cells and are differentially expressed in Hodgkin\u2019s lymphoma","volume":"1","author":"Leonard","year":"2012","journal-title":"Pathogens"},{"key":"10.1016\/j.drudis.2024.104059_b0400","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1016\/j.celrep.2013.11.025","article-title":"PRMT4 blocks myeloid differentiation by assembling a methyl-RUNX1-dependent repressor complex","volume":"5","author":"Vu","year":"2013","journal-title":"Cell Rep"},{"key":"10.1016\/j.drudis.2024.104059_b0405","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbc.2023.105124","article-title":"CARM1 arginine methyltransferase as a therapeutic target for cancer","volume":"299","author":"Santos","year":"2023","journal-title":"J Biol Chem"},{"key":"10.1016\/j.drudis.2024.104059_b0410","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-017-18446-z","article-title":"Identification of a CARM1 inhibitor with potent in vitro and in vivo activity in preclinical models of multiple myeloma","volume":"7","author":"Drew","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.drudis.2024.104059_b0415","doi-asserted-by":"crossref","first-page":"2306","DOI":"10.1016\/j.gendis.2022.03.004","article-title":"BET in hematologic tumors: immunity, pathogenesis, clinical trials and drug combinations","volume":"10","author":"Ma","year":"2023","journal-title":"Genes Dis"},{"key":"10.1016\/j.drudis.2024.104059_b0420","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/978-3-319-18102-8_9","article-title":"BET bromodomain inhibition as a therapeutic approach in hematological malignancies","author":"Vakoc","year":"2015","journal-title":"Histone Recogn"},{"key":"10.1016\/j.drudis.2024.104059_b0425","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1021\/ml4001485","article-title":"Discovery, design, and optimization of isoxazole azepine BET inhibitors","volume":"4","author":"Gehling","year":"2013","journal-title":"ACS Med Chem Lett"},{"key":"10.1016\/j.drudis.2024.104059_b0430","first-page":"727","article-title":"PD-1\/PD-L1 pathway: current researches in cancer","volume":"10","author":"Han","year":"2020","journal-title":"Am J Cancer Res."},{"key":"10.1016\/j.drudis.2024.104059_b0435","first-page":"1","article-title":"BET bromodomain inhibition rescues PD-1-mediated T-cell exhaustion in acute myeloid leukemia","volume":"13","author":"Zhong","year":"2022","journal-title":"Cell Death Dis"},{"key":"10.1016\/j.drudis.2024.104059_b0440","first-page":"1","article-title":"MYC: a multipurpose oncogene with prognostic and therapeutic implications in blood malignancies","volume":"14","author":"Ahmadi","year":"2021","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.drudis.2024.104059_b0445","doi-asserted-by":"crossref","first-page":"3414","DOI":"10.1038\/sj.onc.1205400","article-title":"The proto-oncogene c-myc in hematopoietic development and leukemogenesis","volume":"21","author":"Hoffman","year":"2002","journal-title":"Oncogene"},{"key":"10.1016\/j.drudis.2024.104059_b0450","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1038\/s41375-018-0036-x","article-title":"Targeting MYC in multiple myeloma","volume":"32","author":"Jovanovi\u0107","year":"2018","journal-title":"Leukemia"},{"key":"10.1016\/j.drudis.2024.104059_b0455","article-title":"Human MYC G-quadruplex: from discovery to a cancer therapeutic target","volume":"1874","author":"Wang","year":"2020","journal-title":"Biochim Biophys Acta (BBA) \u2013 Rev Cancer"},{"key":"10.1016\/j.drudis.2024.104059_b0460","first-page":"1275","article-title":"Design, synthesis, and biological evaluation of novel benzimidazolyl isoxazole derivatives as potential c-Myc G4 stabilizers to suppress c-Myc transcription and myeloma growth","author":"Geng","year":"2023","journal-title":"J Mol Struct"},{"key":"10.1016\/j.drudis.2024.104059_b0465","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1182\/bloodadvances.2018027227","article-title":"Leflunomide regulates c-Myc expression in myeloma cells through PIM targeting","volume":"3","author":"Buettner","year":"2019","journal-title":"Blood Adv"},{"key":"10.1016\/j.drudis.2024.104059_b0470","doi-asserted-by":"crossref","DOI":"10.1016\/j.cbi.2023.110687","article-title":"The selective activator protein-1 inhibitor T-5224 regulates the IRF4\/MYC axis and exerts cooperative antimyeloma activity with bortezomib","volume":"384","author":"Tang","year":"2023","journal-title":"Chem Biol Interact"},{"key":"10.1016\/j.drudis.2024.104059_b0475","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.bbrc.2023.09.023","article-title":"HDAC inhibitors: promising agents for leukemia treatment","volume":"680","author":"Deng","year":"2023","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.drudis.2024.104059_b0480","doi-asserted-by":"crossref","first-page":"2957","DOI":"10.1021\/acs.joc.0c02843","article-title":"Iron-catalyzed cycloaddition of amides and 2,3-diaryl-2 H-azirines to access oxazoles via C-N bond cleavage","volume":"86","author":"Zhao","year":"2021","journal-title":"J Org Chem"},{"key":"10.1016\/j.drudis.2024.104059_b0485","first-page":"52","article-title":"T time: Emerging and new therapies for peripheral T-cell lymphoma","author":"Mina","year":"2022","journal-title":"Blood Rev"},{"key":"10.1016\/j.drudis.2024.104059_b0490","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/j.sbi.2005.10.006","article-title":"Structure and activity of enzymes that remove histone modifications","volume":"15","author":"Holbert","year":"2005","journal-title":"Curr Opin Struct Biol"},{"key":"10.1016\/j.drudis.2024.104059_b0495","article-title":"HDAC inhibitors in acute myeloid leukemia","volume":"11","author":"Jos\u00e9-En\u00e9riz","year":"2019","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.drudis.2024.104059_b0500","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1093\/annonc\/mdn792","article-title":"HDAC inhibitor-based therapies and haematological malignancy","volume":"20","author":"Stimson","year":"2009","journal-title":"Ann Oncol"},{"key":"10.1016\/j.drudis.2024.104059_b0505","doi-asserted-by":"crossref","first-page":"471","DOI":"10.4155\/fmc.12.6","article-title":"HDAC inhibitors for the treatment of cutaneous T-cell lymphomas","volume":"4","author":"Rangwala","year":"2012","journal-title":"Future Med Chem"},{"key":"10.1016\/j.drudis.2024.104059_b0510","doi-asserted-by":"crossref","DOI":"10.3390\/cancers11040475","article-title":"HDAC inhibitors exert anti-myeloma effects through multiple modes of action","volume":"11","author":"Imai","year":"2019","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.drudis.2024.104059_b0515","doi-asserted-by":"crossref","first-page":"3023","DOI":"10.1016\/j.bmcl.2009.04.058","article-title":"Isoxazole moiety in the linker region of HDAC inhibitors adjacent to the Zn-chelating group: effects on HDAC biology and antiproliferative activity","volume":"19","author":"Tapadar","year":"2009","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.drudis.2024.104059_b0520","doi-asserted-by":"crossref","first-page":"6157","DOI":"10.1016\/j.bmc.2015.07.069","article-title":"Synthesis of 1,2-benzisoxazole tethered 1,2,3-triazoles that exhibit anticancer activity in acute myeloid leukemia cell lines by inhibiting histone deacetylases, and inducing p21 and tubulin acetylation","volume":"23","author":"Ashwini","year":"2015","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/j.drudis.2024.104059_b0525","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1042\/BJ20071640","article-title":"The Hsp90 molecular chaperone: an open and shut case for treatment","volume":"410","author":"Pearl","year":"2008","journal-title":"Biochem J"},{"key":"10.1016\/j.drudis.2024.104059_b0530","doi-asserted-by":"crossref","first-page":"10317","DOI":"10.3390\/ijms221910317","article-title":"Role of HSP90 in cancer","volume":"22","author":"Birbo","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.drudis.2024.104059_b0535","doi-asserted-by":"crossref","first-page":"779","DOI":"10.3390\/ph5080779","article-title":"Heat shock protein 90 and role of its chemical inhibitors in treatment of hematologic malignancies","volume":"5","author":"Ho","year":"2012","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.drudis.2024.104059_b0540","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.3390\/pharmaceutics14102220","article-title":"Heterocyclic compounds as Hsp90 inhibitors: a perspective on anticancer applications","volume":"14","author":"Ardestani","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.drudis.2024.104059_b0545","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1158\/1535-7163.MCT-07-0149","article-title":"Inhibition of the heat shock protein 90 molecular chaperone in vitro and in vivo by novel, synthetic, potent resorcinylic pyrazole\/isoxazole amide analogues","volume":"6","author":"Sharp","year":"2007","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.drudis.2024.104059_b0550","doi-asserted-by":"crossref","first-page":"984","DOI":"10.3390\/cancers15030984","article-title":"Heat-shock proteins in leukemia and lymphoma: multitargets for innovative therapeutic approaches","volume":"15","author":"Cabaud-Gibouin","year":"2023","journal-title":"Cancers"},{"key":"10.1016\/j.drudis.2024.104059_b0555","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1007\/s12192-008-0035-3","article-title":"Significance of heat-shock protein (HSP) 90 expression in acute myeloid leukemia cells","volume":"13","author":"Flandrin","year":"2008","journal-title":"Cell Stress Chaperones"},{"key":"10.1016\/j.drudis.2024.104059_b0560","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1016\/j.yexcr.2012.05.012","article-title":"Heat shock proteins in hematopoietic malignancies","volume":"318","author":"Mjahed","year":"2012","journal-title":"Exp Cell Res"},{"key":"10.1016\/j.drudis.2024.104059_b0565","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.bcmd.2012.11.002","article-title":"Hsp90 \u2014 a potential prognostic marker in CML","volume":"50","author":"\u017d\u00e1\u010dkov\u00e1","year":"2013","journal-title":"Blood Cells Mol Dis"},{"key":"10.1016\/j.drudis.2024.104059_b0570","doi-asserted-by":"crossref","first-page":"34240","DOI":"10.18632\/oncotarget.26045","article-title":"Heat shock protein 90 inhibitors overcome the resistance to Fms-like tyrosine kinase 3 inhibitors in acute myeloid leukemia","volume":"9","author":"Katayama","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.drudis.2024.104059_b0575","doi-asserted-by":"crossref","first-page":"8592","DOI":"10.1021\/jm201155e","article-title":"Novel 3,4-isoxazolediamides as potent inhibitors of chaperone heat shock protein 90","volume":"54","author":"Baruchello","year":"2011","journal-title":"J Med Chem"},{"key":"10.1016\/j.drudis.2024.104059_b0580","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.radonc.2017.09.043","article-title":"ATR\/CHK1 inhibitors and cancer therapy","volume":"126","author":"Qiu","year":"2018","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.drudis.2024.104059_b0585","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13045-019-0733-6","article-title":"Ataxia telangiectasia and Rad3-related inhibitors and cancer therapy: where we stand","volume":"12","author":"Mei","year":"2019","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.drudis.2024.104059_b0590","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1182\/bloodadvances.2017015214","article-title":"Inhibition of ATR acutely sensitizes acute myeloid leukemia cells to nucleoside analogs that target ribonucleotide reductase","volume":"2","author":"Fordham","year":"2018","journal-title":"Blood Adv"},{"key":"10.1016\/j.drudis.2024.104059_b0595","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.jdermsci.2016.09.010","article-title":"Small-molecule inhibitors of Ataxia Telangiectasia and Rad3 related kinase (ATR) sensitize lymphoma cells to UVA radiation","volume":"84","author":"Biskup","year":"2016","journal-title":"J Dermatol Sci"},{"key":"10.1016\/j.drudis.2024.104059_b0600","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1007\/s12185-017-2226-0","article-title":"DNA damage response and hematological malignancy","volume":"106","author":"Takagi","year":"2017","journal-title":"Int J Hematol"},{"key":"10.1016\/j.drudis.2024.104059_b0605","first-page":"14","article-title":"Targeting the DNA damage response in hematological malignancies","author":"De Mel","year":"2024","journal-title":"Front Oncol"},{"key":"10.1016\/j.drudis.2024.104059_b0610","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114467","article-title":"Discovery of novel coumarin-indole derivatives as tubulin polymerization inhibitors with potent anti-gastric cancer activities","volume":"238","author":"Song","year":"2022","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.drudis.2024.104059_b0615","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2020.107552","article-title":"An overview on anti-tubulin agents for the treatment of lymphoma patients","volume":"211","author":"Barreca","year":"2020","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.drudis.2024.104059_b0620","first-page":"243","article-title":"Development of [1,2]oxazoloisoindoles tubulin polymerization inhibitors: Further chemical modifications and potential therapeutic effects against lymphomas","author":"Barreca","year":"2022","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.drudis.2024.104059_b0625","doi-asserted-by":"crossref","first-page":"91362","DOI":"10.7554\/eLife.91362","article-title":"High-content microscopy reveals a morphological signature of bortezomib resistance","volume":"12","author":"Kelley","year":"2023","journal-title":"Elife"},{"key":"10.1016\/j.drudis.2024.104059_b0630","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-021-90585-w","article-title":"Heat-activated nanomedicine formulation improves the anticancer potential of the HSP90 inhibitor luminespib in vitro","volume":"11","author":"Epp-Ducharme","year":"2021","journal-title":"Sci Rep"},{"key":"10.1016\/j.drudis.2024.104059_b0635","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1158\/2767-9764.CRC-22-0060","article-title":"A phase I study of pelabresib (CPI-0610), a small-molecule inhibitor of BET proteins, in patients with relapsed or refractory lymphoma","volume":"2","author":"Blum","year":"2022","journal-title":"Cancer Res Commun"},{"key":"10.1016\/j.drudis.2024.104059_b0640","doi-asserted-by":"crossref","first-page":"2185","DOI":"10.1002\/cncr.29339","article-title":"Phase 1\/1B trial of the heat shock protein 90 inhibitor NVP-AUY922 as monotherapy or in combination with bortezomib in patients with relapsed or refractory multiple myeloma","volume":"121","author":"Seggewiss-Bernhardt","year":"2015","journal-title":"Cancer"},{"key":"10.1016\/j.drudis.2024.104059_b0645","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1111\/bjh.12215","article-title":"The HSP90 inhibitor NVP-AUY922-AG inhibits the PI3K and IKK signalling pathways and synergizes with cytarabine in acute myeloid leukaemia cells","volume":"161","author":"Walsby","year":"2013","journal-title":"Br J Haematol"},{"key":"10.1016\/j.drudis.2024.104059_b0650","doi-asserted-by":"crossref","first-page":"525","DOI":"10.18632\/oncotarget.491","article-title":"The Hsp90 inhibitor NVP-AUY922-AG inhibits NF-\u03baB signaling, overcomes microenvironmental cytoprotection and is highly synergistic with fludarabine in primary CLL cells","volume":"3","author":"Walsby","year":"2012","journal-title":"Oncotarget"},{"key":"10.1016\/j.drudis.2024.104059_b0655","doi-asserted-by":"crossref","first-page":"e272","DOI":"10.3324\/haematol.2015.126557","article-title":"Experience with HSP90 inhibitor AUY922 in patients with relapsed or refractory non-Hodgkin lymphoma","volume":"100","author":"Oki","year":"2015","journal-title":"Haematologica"},{"key":"10.1016\/j.drudis.2024.104059_b0660","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1038\/nature10509","article-title":"Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia","volume":"478","author":"Dawson","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.drudis.2024.104059_b0665","doi-asserted-by":"crossref","first-page":"4352","DOI":"10.1158\/1078-0432.CCR-23-1429","article-title":"Phase I results of bromodomain and extra-terminal inhibitor PLX51107 in combination with azacitidine in patients with relapsed\/refractory myeloid malignancies","volume":"29","author":"Senapati","year":"2023","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.drudis.2024.104059_b0670","doi-asserted-by":"crossref","first-page":"4927","DOI":"10.1021\/acs.jmedchem.5b00613","article-title":"Structure-based design of \u03b3-carboline analogues as potent and specific BET bromodomain inhibitors","volume":"58","author":"Ran","year":"2015","journal-title":"J Med Chem"},{"key":"10.1016\/j.drudis.2024.104059_b0675","doi-asserted-by":"crossref","first-page":"3887","DOI":"10.1021\/acs.jmedchem.7b00193","article-title":"Structure-based discovery of 4-(6-methoxy-2-methyl-4-(quinolin-4-yl)-9H-pyrimido[4,5-b]indol-7-yl)-3,5-dimethylisoxazole (CD161) as a potent and orally bioavailable BET bromodomain inhibitor","volume":"60","author":"Zhao","year":"2017","journal-title":"J Med Chem"},{"key":"10.1016\/j.drudis.2024.104059_b0680","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1007\/s11899-023-00696-6","article-title":"Pelabresib (CPI-0610): an exciting novel drug for the treatment of myelofibrosis","volume":"18","author":"Ferreira Gomes","year":"2023","journal-title":"Curr Hematol Malig Rep"},{"key":"10.1016\/j.drudis.2024.104059_b0685","doi-asserted-by":"crossref","first-page":"6110","DOI":"10.1021\/acs.jmedchem.8b00483","article-title":"Structure-based discovery of CF53 as a potent and orally bioavailable bromodomain and extra-terminal (BET) bromodomain inhibitor","volume":"61","author":"Zhao","year":"2018","journal-title":"J Med Chem"},{"key":"10.1016\/j.drudis.2024.104059_b0690","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2022.116937","article-title":"Synthesis and biological evaluation of 4-(4-aminophenyl)-6-methylisoxazolo[3,4-b] pyridin-3-amine covalent inhibitors as potential agents for the treatment of acute myeloid leukemia","volume":"70","author":"Kang","year":"2022","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/j.drudis.2024.104059_b0695","doi-asserted-by":"crossref","first-page":"4333","DOI":"10.1016\/j.bmc.2015.06.033","article-title":"Discovery of novel N-(5-(tert-butyl)isoxazol-3-yl)-N\u2032-phenylurea analogs as potent FLT3 inhibitors and evaluation of their activity against acute myeloid leukemia in vitro and in vivo","volume":"23","author":"Xu","year":"2015","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/j.drudis.2024.104059_b0700","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1080\/14756366.2020.1758689","article-title":"Discovery of 5-methyl-N-(2-arylquinazolin-7-yl)isoxazole-4-carboxamide analogues as highly selective FLT3 inhibitors","volume":"35","author":"Im","year":"2020","journal-title":"J Enzyme Inhib Med Chem"},{"key":"10.1016\/j.drudis.2024.104059_b0705","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1016\/S0140-6736(14)60493-1","article-title":"Multiple myeloma","volume":"385","author":"R\u00f6llig","year":"2015","journal-title":"The Lancet"},{"key":"10.1016\/j.drudis.2024.104059_b0710","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/j.pop.2016.07.012","article-title":"Lymphoma","volume":"43","author":"Mugnaini","year":"2016","journal-title":"Primary Care: Clin Office Pract"},{"key":"10.1016\/j.drudis.2024.104059_b0715","first-page":"330","article-title":"Recent advances in managing acute lymphoblastic leukemia","volume":"40","author":"DeAngelo","year":"2020","journal-title":"https:\/\/doi.org\/101200\/EDBK_280175"},{"key":"10.1016\/j.drudis.2024.104059_b0720","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.3324\/haematol.2019.236000","article-title":"Chronic lymphocytic leukemia: from molecular pathogenesis to novel therapeutic strategies","volume":"105","author":"Delgado","year":"2020","journal-title":"Haematologica"},{"key":"10.1016\/j.drudis.2024.104059_b0725","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2019.172641","article-title":"Hematological malignancies and molecular targeting therapy","volume":"862","author":"Shimada","year":"2019","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.drudis.2024.104059_b0730","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.3892\/ijo.2014.2575","article-title":"Preclinical antitumor activity of SST0116CL1: A novel heat shock protein 90 inhibitor","volume":"45","author":"Vesci","year":"2014","journal-title":"Int J Oncol"},{"key":"10.1016\/j.drudis.2024.104059_b0735","doi-asserted-by":"crossref","DOI":"10.3892\/ol.2020.12002","article-title":"Pro-apoptotic activity of novel synthetic isoxazole derivatives exhibiting inhibitory activity against tumor cell growth in vitro","volume":"20","author":"Lampronti","year":"2020","journal-title":"Oncol Lett"},{"key":"10.1016\/j.drudis.2024.104059_b0740","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1158\/2159-8290.CD-17-0902","article-title":"BRD4 profiling identifies critical chronic lymphocytic leukemia oncogenic circuits and reveals sensitivity to PLX51107, a novel structurally distinct BET inhibitor","volume":"8","author":"Ozer","year":"2018","journal-title":"Cancer Discov"},{"key":"10.1016\/j.drudis.2024.104059_b0745","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115924","article-title":"Discovery of (R)-4-(8-methoxy-2-methyl-1-(1-phenylethy)-1H-imidazo[4,5-c]quinnolin-7-yl)-3,5-dimethylisoxazole as a potent and selective BET inhibitor for treatment of acute myeloid leukemia (AML) guided by FEP calculation","volume":"263","author":"Yu","year":"2024","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.drudis.2024.104059_b0750","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1007\/s10495-022-01723-2","article-title":"Targeting lysophosphatidic acid receptor with Ki16425 impedes T cell lymphoma progression through apoptosis induction, glycolysis inhibition, and activation of antitumor immune response","volume":"27","author":"Gupta","year":"2022","journal-title":"Apoptosis"},{"key":"10.1016\/j.drudis.2024.104059_b0755","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1002\/cmdc.201800074","article-title":"Design, synthesis, and in vitro biological evaluation of 3,5-dimethylisoxazole derivatives as BRD4 inhibitors","volume":"13","author":"Li","year":"2018","journal-title":"ChemMedChem"},{"key":"10.1016\/j.drudis.2024.104059_b0760","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2021.104849","article-title":"Design, synthesis, and biological activity evaluation of a series of novel sulfonamide derivatives as BRD4 inhibitors against acute myeloid leukemia","volume":"111","author":"Feng","year":"2021","journal-title":"Bioorg Chem"},{"key":"10.1016\/j.drudis.2024.104059_b0765","doi-asserted-by":"crossref","first-page":"2735","DOI":"10.1038\/s41401-022-00881-y","article-title":"Design, synthesis and pharmacological characterization of N-(3-ethylbenzo[d]isoxazol-5-yl) sulfonamide derivatives as BRD4 inhibitors against acute myeloid leukemia","volume":"43","author":"Zhang","year":"2022","journal-title":"Acta Pharmacol Sin"},{"key":"10.1016\/j.drudis.2024.104059_b0770","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1016\/j.bmcl.2021.128403","article-title":"Design, synthesis, and structure-activity relationship of PD-1\/PD-L1 inhibitors with a benzo[d]isoxazole scaffold","volume":"52","author":"Huang","year":"2021","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.drudis.2024.104059_b0775","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1021\/acs.jmedchem.5b01882","article-title":"Identification of a benzoisoxazoloazepine inhibitor (CPI-0610) of the bromodomain and extra-terminal (BET) family as a candidate for human clinical trials","volume":"59","author":"Albrecht","year":"2016","journal-title":"J Med Chem"},{"key":"10.1016\/j.drudis.2024.104059_b0780","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1038\/leu.2016.355","article-title":"Preclinical activity of CPI-0610, a novel small-molecule bromodomain and extra-terminal protein inhibitor in the therapy of multiple myeloma","volume":"31","author":"Siu","year":"2016","journal-title":"Leukemia"},{"key":"10.1016\/j.drudis.2024.104059_b0785","doi-asserted-by":"crossref","first-page":"2987","DOI":"10.2217\/fon-2022-0484","article-title":"Phase III MANIFEST-2: pelabresib\u00a0+\u00a0ruxolitinib vs placebo\u00a0+\u00a0ruxolitinib in JAK inhibitor treatment-naive myelofibrosis","volume":"18","author":"Harrison","year":"2022","journal-title":"Future Oncol"},{"key":"10.1016\/j.drudis.2024.104059_b0790","doi-asserted-by":"crossref","DOI":"10.3390\/ijms231810222","article-title":"The new microtubule-targeting agent SIX2G induces immunogenic cell death in multiple myeloma","volume":"23","author":"Grillone","year":"2022","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.drudis.2024.104059_b0795","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115372","article-title":"Identification of pyrrolo[3\u2032,4\u2019:3,4]cyclohepta[1,2-d][1,2]oxazoles as promising new candidates for the treatment of lymphomas","volume":"254","author":"Barreca","year":"2023","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.drudis.2024.104059_b0800","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24032356","article-title":"Cytotoxicity of isoxazole curcumin analogs on chronic myeloid leukemia-derived K562 cell lines sensitive and resistant to imatinib","volume":"24","author":"Feriotto","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.drudis.2024.104059_b0805","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2021.105071","article-title":"Glioblastoma-specific anticancer activity of newly synthetized 3,5-disubstituted isoxazole and 1,4-disubstituted triazole-linked tyrosol conjugates","volume":"114","author":"Aissa","year":"2021","journal-title":"Bioorg Chem"},{"key":"10.1016\/j.drudis.2024.104059_b0810","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2021.105334","article-title":"Synthesis, in vitro anticancer activity and in silico studies of certain isoxazole-based carboxamides, ureates, and hydrazones as potential inhibitors of VEGFR2","volume":"116","author":"Abou-Seri","year":"2021","journal-title":"Bioorg Chem"},{"key":"10.1016\/j.drudis.2024.104059_b0815","doi-asserted-by":"crossref","first-page":"2984","DOI":"10.1182\/blood-2009-05-222034","article-title":"AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML)","volume":"114","author":"Zarrinkar","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.drudis.2024.104059_b0820","doi-asserted-by":"crossref","first-page":"7808","DOI":"10.1021\/jm9007533","article-title":"Identification of N-(5-tert-butyl-isoxazol-3-yl)-N\u2019-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea dihydrochloride (AC220), a uniquely potent, selective, and efficacious FMS-like tyrosine kinase-3 (FLT3) inhibitor","volume":"52","author":"Chao","year":"2009","journal-title":"J Med Chem"},{"key":"10.1016\/j.drudis.2024.104059_b0825","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.2147\/DDDT.S198950","article-title":"Quizartinib (AC220): a promising option for acute myeloid leukemia","volume":"13","author":"Zhou","year":"2019","journal-title":"Drug Des Devel Ther"},{"key":"10.1016\/j.drudis.2024.104059_b0830","article-title":"A series of novel aryl-methanone derivatives as inhibitors of FMS-like tyrosine kinase 3 (FLT3) in FLT3-ITD-positive acute myeloid leukemia","author":"Sellmer","year":"2020","journal-title":"Published Online"},{"key":"10.1016\/j.drudis.2024.104059_b0835","doi-asserted-by":"crossref","DOI":"10.1016\/j.yexcr.2023.113759","article-title":"Novel c-Myc G4 stabilizer EP12 promotes myeloma cytotoxicity by disturbing NF-\u03baB signaling","volume":"431","author":"Yao","year":"2023","journal-title":"Exp Cell Res"},{"key":"10.1016\/j.drudis.2024.104059_b0840","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1007\/s11030-021-10208-4","article-title":"Design, synthesis and biological evaluation of isoxazole-containing biphenyl derivatives as small-molecule inhibitors targeting the programmed cell death-1\/ programmed cell death-ligand 1 immune checkpoint","volume":"26","author":"Zhu","year":"2022","journal-title":"Mol Divers"},{"key":"10.1016\/j.drudis.2024.104059_b0845","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1038\/leu.2012.52","article-title":"Selective FLT3 inhibition of FLT3-ITD+ acute myeloid leukaemia resulting in secondary D835Y mutation: a model for emerging clinical resistance patterns","volume":"26","author":"Moore","year":"2012","journal-title":"Leukemia"},{"key":"10.1016\/j.drudis.2024.104059_b0850","doi-asserted-by":"crossref","DOI":"10.1016\/j.ultsonch.2021.105748","article-title":"Ultrasound-assisted one-pot three-component synthesis of new isoxazolines bearing sulfonamides and their evaluation against hematological malignancies","volume":"78","author":"Talha","year":"2021","journal-title":"Ultrason Sonochem"},{"key":"10.1016\/j.drudis.2024.104059_b0855","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12943-023-01721-1","article-title":"Targeting Pim kinases in hematological cancers: molecular and clinical review","volume":"22","author":"Bellon","year":"2023","journal-title":"Mol Cancer"},{"key":"10.1016\/j.drudis.2024.104059_b0860","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1080\/10428194.2020.1742900","article-title":"Repurposing leflunomide for relapsed\/refractory multiple myeloma: a phase 1 study","volume":"61","author":"Rosenzweig","year":"2020","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.drudis.2024.104059_b0865","doi-asserted-by":"crossref","first-page":"5653","DOI":"10.3390\/molecules26185653","article-title":"The mitochondria-independent cytotoxic effect of leflunomide on RPMI-8226 multiple myeloma cell line","volume":"26","author":"Adamczuk","year":"2021","journal-title":"Molecules"},{"issue":"16","key":"10.1016\/j.drudis.2024.104059_bib866","doi-asserted-by":"crossref","first-page":"4735","DOI":"10.1016\/j.bmc.2018.08.013","article-title":"Design, synthesis and structure-activity relationship of diaryl-ureas with novel isoxazol(3,4-b)pyridine-3-amino-structure as multi-target inhibitors against receptor tyrosine kinase","volume":"26","author":"Shi","year":"2018","journal-title":"Bioorg Med Chem"}],"container-title":["Drug Discovery Today"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644624001843?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644624001843?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,7]],"date-time":"2024-10-07T23:14:44Z","timestamp":1728342884000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1359644624001843"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":174,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["S1359644624001843"],"URL":"https:\/\/doi.org\/10.1016\/j.drudis.2024.104059","relation":{},"ISSN":["1359-6446"],"issn-type":[{"value":"1359-6446","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeting hematological malignancies with isoxazole derivatives","name":"articletitle","label":"Article Title"},{"value":"Drug Discovery Today","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.drudis.2024.104059","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"104059"}}